Inclusion Criteria:

- Neck and head epidermoid carcinoma histologically proved. Patient with an ENT
epidermoid tumor can be included in the study if this relapse is located in an area
not irradiated yet.

- At least tumor classified T2NXM0

- Patient who can be picked up in a first surgery with a curative purpose or who must
have a necessity's surgery (cervical curettage for voluminous adenopathies before
radiotherapy)

- Patient without clinical or radiological sign of metastatic disease

- Good general status (OMS ≤ 2)

- Patient able to ingest food.

- Age ≥ 18 years

- Well-informed written consent, signed by the patient.

- Patient with sickness benefit

Exclusion Criteria:

- Patient with relapse ever treated by radiotherapy

- Other prospective study's participation

- Recent and massive digestive haemorrhage

- Medical contra-indication like main general status alteration, uncontrolled serious
infectious disease, main uncontrolled metabolic anomaly ongoing.

- Pre-existent pulmonary pathology (BPCO, pleurisy, lymphangitis, interstitial
syndrome)

- Severe cardiac pathology (stage 3 or 4 cardiac insufficiency, unstable angina
pectoris, uncontrolled arrhythmia, myocardium's infarction antecedent during the year
that precede the inclusion.

- Ophthalmic pathology antecedent concerning the ocular surface or lens-carrier

- Concomitant administration, by local or general tract, of drug responsible for ocular
drought or which could delay the epithelial cicatrization

- Less than 1000 polynuclear neutrophil leucocytes or less than 75000 blood-platelets
at inclusion

- Bilirubin at higher concentration than one point five times the normal

- Renal insufficiency (glomerular filtration flow ≤ 40 ml/min)calculated in accordance
with Cockroft's formula

- Tacking of Beta blockers, amiodarone, NSAIDs, bleomycin, just before or during the
study

- Pregnant or nursing women

- Patient under guardianship or trusteeship.